✣OncoGonFROM DISCOVERY TO IMPACT
HomeAssetsTriage & Prioritisation
3D Tumour IntelligenceExperimentsImagingSegmentation & QCResponse AnalysisAI Analysis (OSIEL)
Qualified AssetsIndustry & Data RoomCollaborationReports & Insights
Admin
Home3D Tumour IntelligenceOV-006
Loading study workspace…
3D Tumour Intelligence

OV-006

Scientific ReviewRESEARCH MODE

Ovarian Signature Validation

AssetOGC-OV-207CancerOvarian CancerSubtypeHigh-grade serousModelPatient-derived OrganoidLead ScientistDr. L. Chen
Review DiscussionAsk OSIEL About This Study

Study Summary

Scientific context and protocol

Response signature may stratify organoid sensitivity.

Linked AssetOGC-OV-207
Cancer / SubtypeOvarian Cancer · High-grade serous
ModelPatient-derived Organoid
InvestigatorsDr. Sarah Mokoena · Dr. J. Patel
ProtocolOG-PROT-ORG-018
Start Date2026-09-12
Current StageScientific Review
Data ModeRESEARCH

Key Result

Day 7 response · illustrative scientific data

DRUG B

Strong Response

Review and replicate confirmation pending.

Viability18%
Tumour size-71%
Confidence0.92

Treatment Overview

Control and two intervention groups

Control0 · 3 replicates
Drug A0.1 µM · 3 replicates
Drug B0.8 µM · 3 replicates

Timepoints

Longitudinal image and response capture

Day 0Day 3Day 7

Current analytical timepoint: Day 7.

Study Timeline

Completed, current, and upcoming workflow

Setup
Samples
Treatment
Imaging
Segmentation & QC
Response Analysis
Scientific Review
Approved Result

Current Alerts

Research review required

Scientific Review review pendingNeeds Review
Passed QC status requires confirmationNeeds Review

Study Context

Current scientific record

StageScientific Review
QCPassed
ProtocolOG-PROT-ORG-018
Images110
Last Updated2026-09-27

Current Attention

Research review queue

Scientific Review review pendingPassed QC status requires confirmation
Research data · human review required.